Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEND-1 plus Chemotherapy in Advanced PDAC
NCT06261359Phase 2Recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Mar 2024
- Primary completion
- Apr 2025
- Modality
- Cyclic Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pancreatic ductal adenocarcinoma (PDAC) comparing CEND-1 Arm with Placebo Arm (2 arms). Primary endpoint: Objective Response Rate at 36 months. Started Mar 2024; status: recruiting.
02
Drugs
certepetide
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06261359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06261359.